Viewing data from:

CLARAVIS

ANDA

ISOTRETINOIN | A076135 | TEVA PHARMACEUTICALS USA

3 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-10-21 | 5 NDCs

Highest NADAC/Unit

$2.19

per ea

Lowest NADAC/Unit

$1.93

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00555105756CLARAVIS 40 MG CAPSULE	$2.19	EA	Generic	—	2026-10-21
00555105786CLARAVIS 40 MG CAPSULE	$2.19	EA	Generic	—	2026-10-21
00555105686CLARAVIS 30 MG CAPSULE	$2.01	EA	Generic	—	2026-10-21
00555105556CLARAVIS 20 MG CAPSULE	$1.93	EA	Generic	—	2026-10-21
00555105586CLARAVIS 20 MG CAPSULE	$1.93	EA	Generic	—	2026-10-21

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

Medicare Part D Spending

CMS annual spending data for Claravis (2024)

Total Spending

$593K

Total Claims

4,013

Beneficiaries

1,671

Avg Cost/Unit

$3.35

Spending Trend

$1.2M(2019)→$1.0M(2020)→$960K(2021)→$796K(2022)→$718K(2023)→$593K(2024)

YoY Change:-27.4%

5yr CAGR:-8.5%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain8 active DMFs2 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

OLON SPAISOTRETINOIN

DMF 74851988

JIANGXI HENGXIANG PHARMCEUTICAL TECHNOLOGY CO LTDISOTRETINOIN (NON-STERILE BULK FORM)

DMF 191912005

HAS HEALTHCARE ADVANCED SYNTHESIS SAISOTRETINOIN

DMF 199182006

CHONGQING HUAPONT PHARMACEUTICAL CO LTDISOTRETINOIN

DMF 216532008

BIOPHORE INDIA PHARMACEUTICALS PVT LTDISOTRETINOIN

DMF 274842013

SUN PHARMACEUTICAL INDUSTRIES LTDISOTRETINOIN USP

DMF 325172018

CHONGQING HUAPONT PHARMACEUTICAL CO LTDISOTRETINOIN

DMF 345102020

HETERO DRUGS LTDISOTRETINOIN

DMF 368572022

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveISOTRETINOIN USP (NON-STERILE BULK)

DMF 151692000

IPCA LABORATORIES LTDInactiveISOTRETINOIN USP

DMF 226162009

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — 40MG

AB1

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Apr 11, 2003

No patent or exclusivity listings for this strength.

#002 — 20MG

AB1

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Apr 11, 2003

#003 — 30MG

AB1

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: May 11, 2006